高级检索
当前位置: 首页 > 详情页

Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]First Peoples Hosp Shuangliu Dist, Dept Urol, Chengdu, Peoples R China [2]Tsinghua Univ, Sch Clin Med, Beijing, Peoples R China [3]Kunming Med Univ, Affiliated Hosp 1, Dept Urol, Kunming, Peoples R China [4]Univ Elect Sci & Technol China, Med Sch, Chengdu, Peoples R China [5]Kunming Med Univ, Affiliated Hosp 1, Med Imaging Dept, Kunming, Peoples R China
出处:
ISSN:

关键词: prostate biopsy prostate cancer prostate imaging reporting and data system score prostate-specific antigen density (PSAD) clinically significant prostate cancer (csPCa)

摘要:
Globally, Prostate cancer (PCa) is the second most common cancer in the male population worldwide, but clinically significant prostate cancer (CSPCa) is more aggressive and causes to more deaths. The authors aimed to construct the risk category based on Prostate Imaging Reporting and Data System score version 2.1 (PI-RADS v2.1) in combination with Prostate-Specific Antigen Density (PSAD) to improve CSPCa detection and avoid unnecessary biopsy. Univariate and multivariate logistic regression and receiver-operating characteristic (ROC) curves were performed to compare the efficacy of the different predictors. The results revealed that PI-RADS v2.1 score and PSAD were independent predictors for CSPCa. Moreover, the combined factor shows a significantly higher predictive value than each single variable for the diagnosis of CSPCa. According to the risk stratification model constructed based on PI-RADS v2.1 score and PSAD, patients with PI-RADS v2.1 score of <= 2, or PI-RADS V2.1 score of 3 and PSA density of <0.15 ng/mL(2), can avoid unnecessary of prostate biopsy and does not miss clinically significant prostate cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2022]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]First Peoples Hosp Shuangliu Dist, Dept Urol, Chengdu, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52537 今日访问量:0 总访问量:1562 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)